Under the Paperwork F	Reduction Act of 19	95, no persor	ns are required to respond to a	a collection of i	information unless it	t displays a valid OMB control number.	
TRANSPOR	TT A 1	-	Application Number	er	10/747,796		
TRANSMITTAL			Filing Date First Named Inventor		December 29, 2003 Thomas E. Barta		
FORM							
			Art Unit	•	1625		
(to be used for all corresponde	ence after initial i	filina)	Examiner Name		TBA	· · · · · · · · · · · · · · · · · · ·	
Total Number of Pages in This			Attorney Docket N	umber	3124/5A/US (6794-0000	S 31134A/USA 017/DVF)	
		ENCLO	SURES (check all the	at apply)			
Fee Transmittal Form		Drawing(s			After Allow	ance Communication to TC	
Fee Attached		Licensing-	related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendment / Reply		Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final		Provisiona	Convert to a Application		Proprietary	Information	
Affidavits/declaration(			Attorney, Revocation f Correspondence Add	ress	Status Letter		
Extension of Time Request			Disclaimer		Other Enclosure(s) (please identify below):		
Express Abandonment Request		on of CD(a)		Form HDP-1449 1 Reference Return Receipt Postcard			
Supplemental Information		dscape Table on CD		Return Receip	residard		
Certified Copy of Priority Document(s)		Remarks					
Reply to Missing Parts/ Incomplete Application Reply to Missing Part under 37 CFR1.52 or							
		URE OF A	APPLICANT, ATTO	RNEY, O	R AGENT		
Firm	Harr	ness, Diekey	& Pierce, P.L.C.				
Signature		W NH					
Printed Name David M. Gryte							
Date January 31, 200		Reg. No. 41,809					
	CE	RTIFICA	TE OF TRANSMIS	SION/MAI	ILING		
I hereby certify that this correspond to the Service with sufficient posta Alexandria, VA 22313-1450 o	ge as first cla	ass mail i	in an envelope addre				
Typed or printed name David M. Gryte			11_		Express Mail Label No.	EV 327050975 US	
Signature / / //			VI		Date	January 31, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Thomas E. Barta, et al.

Serial No:

10/747,796

Filed:

December 29, 2003

For:

Aromatic Sulfone Hydroxamic Acid Metalloprotease Inhibitors

Confirmation No: Group Art Unit:

6418

Eveninen

1625

Examiner:

TBA

Attorney Ref:

3124/5A/US

Pfizer Ref:

31134A/USA

HDP Ref:

6794-000017/DVF

January 31, 2005

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Madam/Sir:

71 071 17 6 V

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed Form PTO-1449.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that the cited document be given thorough consideration, and that the Examiner cite it in the prosecution history of the present application by initialing the Form PTO-1449 next to the citation. Applicants request such initialing even if the Examiner does not consider: (1) the document to be sufficiently pertinent to use in a rejection; (2) the document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with. Applicants make this request so that the document becomes cited on the face of a patent issuing on the present application.

Applicants submit this supplemental information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing the document are not admitting that it is necessarily relevant or prior art. Applicants intend no representation that the listed document represents the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance the document listed on the attached form even if not initialed.

Supplemental Information Disclosure Statement Appl. No. 10/747,796 January 31, 2005

The reference cited in this information disclosure statement is a published U.S. patent application. A copy of it therefore is not being provided in accordance with 37 C.F.R. §1.98(d) and MPEP §609 Part III(A)(2). The pending claim set from this application, however, is being enclosed because the claims have been amended and therefore differ from the claims in the published application. Applicants are happy to provide a copy of the cited application upon request from the Examiner.

Applicants request early and favorable consideration of this patent application.

\* \* \* \* \* \* \* \*

Applicants believe that they do not owe any fee in connection with this information disclosure statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Respectfully submitted,

David M. Gryte, PTO Reg. No. 41,809

Harness, Dickey & Pierce 7700 Bonhomme, Suite 400 St. Louis, Missouri 63105

(314) 726-7500 (tel)

(314) 726-7501 (fax)

## CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on January 31, 2005 with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

DMG/PML enclosures

\o\ \o\	PE CIO
AL	N 3 1 2005
BATTERY.	e reader of

FORM HDP-1449 (Based on Form PTO-1449)

## PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.	SERIAL NO.	
3124/5A/US (Pfizer Ref. 31134A/USA)	10/747,796	
APPLICANT		
Thomas E. Barta et al.		
FILING DATE	GROUP	
December 29, 2003	1625	

U.S. PATENT D	OCUMENTS	8				
Ref. Desig.	Examiner's Initials	Document Number	Date	Name		(If appropriate) Filing Date
1. (pending claims enclosed)		U.S. Patent Appl. Publ. No. 2004-0167182 (Appl. No. 10/603,441), including pending claims		Becker et al.	514/357	6/25/03

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translati Yes	ion No
,							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)				
Ref. Desig.	Examiner's Initials			

Examiner:	Date Considered:	